/A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator’s choice therapy in participants with relapsed small cell lung cancer (DLLEVATE).

Citation Map

Citing

Cited By

The articles shown here are a subset.See the full list of articles below.

Citing (0)

Sort By:

Data not found

Cited By (0)

Sort By: